Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport®) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicentre study

Hartmut Göbel, Axel Heinze, Gerhard Reichel, Harald Hefter, Reiner Benecke and on behalf of the Dysport myofascial pain study group

Botulinum type A toxin (BoNT-A) has antinociceptive and muscle-relaxant properties and may help relieve the symptoms of myofascial pain syndrome. This study evaluated the efficacy and tolerability of BoNT-A  (Dysport®) in patients with myofascial pain syndrome of the upper back. Patients with moderate-to-severe myofascial pain syndrome affecting cervical and/or shoulder muscles were randomized to BoNT-A or saline injections which were made into the 10 most tender trigger points. The results showed that BoNT-A resulted in a significantly less pain in all outcomes. The authors conclude that in patients with upper back myofascial pain syndrome, injections of 400 Ipsen units of Dysport® at 10 individualised trigger points significantly improved pain levels 4–6 weeks after treatment.

Pain, Volume 125, Issues 1-2, November 2006, Pages 82-88

View Abstract

Full article with Athens login

Sensorimotor Impairment in Neck Pain

Join Chris Worsfold in this short online course to learn about the evaluation and rehabilitation of sensorimotor impairment in patients with neck pain.